Navigation Links
Study shows how normal cells influence tumor growth
Date:10/21/2009

COLUMBUS, Ohio It was once thought that the two communities of cells within a cancerous breast tumor fast-growing malignant cells and the normal cells that surround them existed independently, without interaction. Then evidence emerged indicating that the normal-looking cells encouraged cells within the tumor to become malignant, but how the one community influenced the other wasn't known.

A new study led by Ohio State University cancer researchers published in the Oct. 22 issue of Nature has begun solving the mystery. It shows for the first time that the loss of a gene called PTEN from one type of those surrounding cells can dramatically alter the tumor environment in ways that foster tumor growth.

"Our findings reveal a new role for this gene in the tumor environment, which could lead to entirely new treatments for breast cancer and perhaps other solid tumors using agents that target cells surrounding the tumor, as well as the cancer cells themselves," says co-principal investigator Gustavo Leone, associate professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The findings should also improve the understanding of breast cancer and of other conditions that are influenced by the local tissue environment such as autoimmune disease, lung fibrosis and neurodegenerative diseases.

The PTEN gene produces a protein that is a key regulator of cell metabolism, and it is lost in many human cancers.

This new study shows that when PTEN is lost in fibroblasts, a principle cell component of the tissue that surrounds a tumor, it dramatically alters the structure and biochemical make-up of the tumor environment. For example, levels of the fibrous protein collagen rise, inflammatory cells called macrophages migrate into the tumor and the number of tumor blood vessels increases. These events all favor tumor growth.

"Our study demonstrates that PTEN in surrounding fibroblasts plays an important role in suppressing cancer development," says co-principal investigator Michael Ostrowski, professor and chair of molecular and cellular biochemistry and co-director of the cancer center's Molecular Biology and Cancer Genetics Program.

To show this, Leone, Ostrowski and their colleagues removed PTEN from fibroblasts in the mammary glands of mice. They were surprised to discover that PTEN regulates a second gene, called Ets2, which executes the changes that occur in the tumor environment when PTEN is lost.

"Remarkably, this animal model mimics many of the features observed in human breast cancer, " Leone says, "so it should help us evaluate experimental agents that might be used in combination therapies that target faulty cells in the tumor environment, as well as cancer cells."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Sex With a Partner Makes Evolutionary Sense: Study
2. Research partnership will study how electronic medical records can address genetics of drug safety
3. Internet fuels virtual subculture for sex trade, study finds
4. $8 million NIH grant for heart cell development and study
5. Study Forecasts More Young Doctors in Future
6. Frequency of Hospital Professional Liability Claims Increasing After Years of Declines, Says Aon and ASHRM Study
7. New Study Details Complex Health Care Needs of Medicaids Highest-Need, Highest-Cost Populations
8. Vascular Study Group of New England Selects Clinical Data Pathways, Powered by M2S, as Quality Improvement Registry Provider
9. Illness often undiscovered and undertreated among the uninsured: Harvard study
10. Thyroid surgery safe for older patients, study finds
11. New National Study of Crash-Involved Children Reaffirms Recommendations for Booster Seat Through Age 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... San Jose, Calif (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area ... save lives with “Make ‘em Bleed,” the most widely attended series of blood drives in ... 900 units of blood over the past 4 years -- enough to have helped to ...
(Date:7/26/2017)... ... ... It may be hard to imagine that the basic necessities that developed countries ... that many developed countries consider rare or eradicated, like measles, are still a rite ... an upcoming segment of "Success Files", actor Rob Lowe will introduce a new segment ...
(Date:7/26/2017)... ... July 27, 2017 , ... It's time to sign up for the ... great benefits," says Kathy Heshelow, founder of Sublime Naturals and author of numerous books on ... oil each month, mailed by the 5th. , Two items are included ...
(Date:7/26/2017)... ... ... “We are thrilled to be partnering with Six Month Smiles to work ... in real time,” said Keith English, LocalMed CEO. “Allowing patients the ability to schedule ... Month Smiles patients to their providers.” , Each month, over 25,000 patients research Six ...
(Date:7/26/2017)... ... 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: ... the development of pharmaceutical and consumer products, announces the operational numbers of its ... Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: